United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its ...

Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, ...

Most compounding and concentrates firms saw positive results in 2024. And in recent interviews, executives with those companies said they're hoping to keep those good vibes rolling into 2025. "Many of ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Financial support for this research came from MIUR (Italian Ministry of Education, University and Scientific Research). Our news journalists obtained a quote from the research from the University of ...